Ouar Zahia, Bens Marcelle, Vignes Caroline, Paulais Marc, Pringel Claudine, Fleury Jocelyne, Cluzeaud Francçoise, Lacave Roger, Vandewalle Alain
INSERM U478, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, BP 416, 75870 Paris Cedex 18, France.
Biochem J. 2003 Feb 15;370(Pt 1):185-93. doi: 10.1042/BJ20021411.
It has been suggested that the inappropriate sequestration of weak-base chemotherapeutic drugs in acidic vesicles by multidrug-resistance (MDR) cells contributes to the mechanisms of drug resistance. The function of the acidic lysosomes can be altered in MDR cells, and so we investigated the effects of lysosomotropic agents on the secretion of lysosomal enzymes and on the intracellular distribution of the weak-base anthracycline daunomycin in drug-resistant renal proximal tubule PKSV-PR(col50) cells and their drug-sensitive PKSV-PR cell counterparts. Imaging studies using pH-dependent lysosomotropic dyes revealed that drug-sensitive and drug-resistant cells exhibited a similar acidic lysosomal pH (around 5.6-5.7), but that PKSV-PR(col50) cells contained more acidic lysosomes and secreted more of the lysosomal enzymes N -acetyl-beta-hexosaminidase and beta-glucuronidase than their parent PKSV-PR cells. Concanamycin A (CCM A), a potent inhibitor of the vacuolar H(+)-ATPase, but not the P-glycoprotein modulator verapamil, stimulated the secretion of N -acetyl-beta-hexosaminidase in both drug-sensitive and drug-resistant cells. Fluorescent studies and Percoll density gradient fractionation studies revealed that daunomycin accumulated predominantly in the lysosomes of PKSV-PR(col50) cells, whereas in PKSV-PR cells the drug was distributed evenly throughout the nucleo-cytoplasmic compartments. CCM A did not impair the cellular efflux of daunomycin, but induced the rapid nucleo-cytoplasmic redistribution of the drug in PKSV-PR(col50) cells. In addition, CCM A and bafilomycin A1 almost completely restored the sensitivity of these drug-resistant cells to daunomycin, doxorubicin and epirubicin. These findings indicate that lysosomotropic agents that impair the acidic-pH-dependent accumulation of weak-base chemotherapeutic drugs may reverse anthracycline resistance in MDR cells with an expanded acidic lysosomal compartment.
有人提出,多药耐药(MDR)细胞在酸性囊泡中不恰当地隔离弱碱性化疗药物是耐药机制的一部分。MDR细胞中酸性溶酶体的功能可能会发生改变,因此我们研究了溶酶体促渗剂对耐药性肾近端小管PKSV-PR(col50)细胞及其药物敏感的PKSV-PR细胞对应物中溶酶体酶分泌以及弱碱性蒽环类药物柔红霉素细胞内分布的影响。使用pH依赖性溶酶体促渗染料的成像研究表明,药物敏感细胞和耐药细胞的酸性溶酶体pH值相似(约5.6 - 5.7),但PKSV-PR(col50)细胞比其亲本PKSV-PR细胞含有更多的酸性溶酶体,并且分泌更多的溶酶体酶N - 乙酰 - β - 己糖胺酶和β - 葡萄糖醛酸酶。空泡H(+) - ATP酶的强效抑制剂 concanamycin A(CCM A),而非P - 糖蛋白调节剂维拉帕米,刺激了药物敏感细胞和耐药细胞中N - 乙酰 - β - 己糖胺酶的分泌。荧光研究和Percoll密度梯度分级分离研究表明,柔红霉素主要积聚在PKSV-PR(col50)细胞的溶酶体中,而在PKSV-PR细胞中,药物均匀分布在整个核质区室。CCM A并未损害柔红霉素的细胞外排,但诱导了PKSV-PR(col50)细胞中药物的快速核质重新分布。此外,CCM A和巴弗洛霉素A1几乎完全恢复了这些耐药细胞对柔红霉素、阿霉素和表柔比星的敏感性。这些发现表明,损害弱碱性化疗药物依赖于酸性pH值积聚的溶酶体促渗剂可能会逆转具有扩大酸性溶酶体区室的MDR细胞中的蒽环类药物耐药性。